TY  - JOUR
AU  - Baumgartner, Tobias
AU  - Freyberg, Moritz
AU  - Campetella, Lucia
AU  - Crijnen, Yvette
AU  - Dargvainiene, Justina
AU  - Behning, Charlotte
AU  - Bien, Christian G
AU  - Rada, Anna
AU  - Prüss, Harald
AU  - Rössling, Rosa
AU  - Kovac, Stjepana
AU  - Strippel, Christine
AU  - Thaler, Franziska S
AU  - Eisenhut, Katharina
AU  - Lewerenz, Jan
AU  - Becker, Felicitas
AU  - Reinecke, Raphael
AU  - Malter, Michael Peter
AU  - Sühs, Kurt-Wolfram
AU  - Tauber, Simone C
AU  - Von Podewils, Felix
AU  - Melzer, Nico
AU  - Wandinger, Klaus-Peter
AU  - Fernandez Ceballos, Romina-Anna-Maria
AU  - Kuhle, Jens
AU  - Berger, Klaus
AU  - Bauer, Tobias
AU  - Rüber, Theodor
AU  - Racz, Attila
AU  - Becker, Albert J
AU  - Pitsch, Julika
AU  - Kuhlenbäumer, Gregor
AU  - Muñiz-Castrillo, Sergio
AU  - Honnorat, Jerome
AU  - Titulaer, Maarten J
AU  - Leypoldt, Frank
AU  - Surges, Rainer
TI  - Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis: Long-Term Outcome in 236 Patients.
JO  - Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
VL  - 12
IS  - 6
SN  - 2332-7812
CY  - Philadelphia, Pa.
PB  - Wolters Kluwer
M1  - DZNE-2026-00014
SP  - e200469
PY  - 2025
AB  - Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy (AEAE) and persistent cognitive deficits. The aim of this large multicentric retrospective observational cohort study was to assess long-term outcomes of patients with anti-LGI1 encephalitis regarding seizures and AEAE and to identify associated factors.We included patients with anti-LGI1 encephalitis from 3 national referral centers/consortia meeting the following inclusion criteria: (I) definite LGI1 limbic encephalitis (Graus criteria); (II) occurrence of seizures; and (III) follow-up period ≥24 months. We aimed to (1) determine the risk of seizure recurrence (ROSR) on remission, (2) investigate clinical and paraclinical biomarkers for an effect on time to seizure remission using Cox proportional hazard modeling (n = 188), and (3) assess the risk of AEAE and determine associated factors (n = 236).AEAE was observed in 5.9
KW  - Humans
KW  - Female
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Adult
KW  - Aged
KW  - Epilepsy: etiology
KW  - Epilepsy: epidemiology
KW  - Autoantibodies: blood
KW  - Seizures: etiology
KW  - Encephalitis: complications
KW  - Encephalitis: immunology
KW  - Autoimmune Diseases of the Nervous System: complications
KW  - Autoimmune Diseases of the Nervous System: immunology
KW  - Autoimmune Diseases of the Nervous System: therapy
KW  - Limbic Encephalitis: complications
KW  - Limbic Encephalitis: immunology
KW  - Follow-Up Studies
KW  - Intracellular Signaling Peptides and Proteins: immunology
KW  - Young Adult
KW  - Autoantibodies (NLM Chemicals)
KW  - LGI1 protein, human (NLM Chemicals)
KW  - anti-leucine-rich glioma-inactivated 1 autoantibody (NLM Chemicals)
KW  - Intracellular Signaling Peptides and Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40953325
C2  - pmc:PMC12440303
DO  - DOI:10.1212/NXI.0000000000200469
UR  - https://pub.dzne.de/record/283118
ER  -